Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BCMA CAR-T (BH002) for Refractory SLE
NCT06350110Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BAH242 in systemic lupus erythematosus (SLE), sponsored by Essen BioTech. Primary endpoint: Incidence and severity of dose limiting toxicities (DLTs) at 28 days. Started Jul 2024; status: recruiting.
02
Drugs
BAH242
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06350110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350110.